RE:RE:RE:RE:RE:RE:Unfortunately the market perceives phase one as a failure Yes our great phase one efficacy results were achieved treating THE WORST OF THE WORST!!!!! Patients pharma had given up on, we treated ONCE, and achieved amazing efficacy.
Give you something else to chew on. TLTs treatment was used as a last resort for the worst of the worst, after many treatments failed!!!! WHAT IF OUR TREATMENT WAS THE FIRST THING USED, WHEN CANCER IS FIRST DETECTED, THE VERY FIRST TREATMENT ADMINISTERED, ONCE OR TWICE, YOU WANT SOME AMAZING RESULTS??? JUST WATCH WHEN THAT HAPPENS!!
Macer wrote: Actually, making the criteria for phase 1 so specificc (i.e. only enrolling patients that had failed conventional treatment) likely increased the likelihood that uttuc was more prevalent. 50% of patient that fail bcg treatment are identified as having uttuc or high risk for it.
that is also the reason why phase 2 will be that much more successful. It will be designed to treat all comers, not just the highest risk patients. If people could only understand that there would be a much higher demand for tlt shares. We are dealing with timelines and financing but the science is legit.
macer